Well-differentiated neuroendocrine carcinoma

Clinical trials for Well-differentiated neuroendocrine carcinoma explained in plain language.

Never miss a new study

Get alerted when new Well-differentiated neuroendocrine carcinoma trials appear

Sign up with your email to follow new studies for Well-differentiated neuroendocrine carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for rare cancer: drug combo targets Tough-to-Treat neuroendocrine tumors

Disease control Recruiting now

This study tests a combination of two drugs, lenvatinib and pembrolizumab, in people with a rare and aggressive type of neuroendocrine tumor called well-differentiated grade 3 (WD G3). The goal is to see if the treatment can shrink tumors or stop them from growing. About 29 adult…

Matched conditions: WELL-DIFFERENTIATED NEUROENDOCRINE CARCINOMA

Phase 2 • Sponsor: University of California, San Francisco • Aim: Disease control

Last updated Jun 27, 2026 11:02 UTC

Well-differentiated neuroendocrine carcinoma

Get alerted when new Well-differentiated neuroendocrine carcinoma trials appear

New hope for rare cancer: drug combo targets Tough-to-Treat neuroendocrine tumors